ESLAEstrella Immunopharma, Inc.vs its industry peers
A metric-by-metric comparison of Estrella Immunopharma, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ESLAThis | $24M#9 | — | — | — | — | — | — | — | — | — | -50.9%#8 | — |
| TIL | $49M#2 | — | 0.5x#2 | — | -100.0%#7 | 3.7%#7 | — | -66.5%#3 | — | — | -66.5%#11 | — |
| SCLX | $46M#3 | — | — | 1.5x#1 | -46.5%#5 | -413.8%#15 | -1143.7%#3 | — | — | 4#1 | -74.0%#12 | — |
| MGX | $42M#4 | — | 0.4x#1 | 1.7x#2 | -51.8%#6 | -12.6%#9 | -380.9%#2 | -78.1%#5 | — | — | -48.0%#6 | — |
| ATYR | $36M#5 | — | 0.7x#4 | 188.7x#5 | -19.1%#3 | -15.8%#10 | -40856.3%#6 | -151.9%#7 | -202.0%#2 | — | -65.0%#10 | — |
| ALGS | — | — | — | — | -39.5%#4 | 81.6%#2 | -4024.9%#4 | -75.9%#4 | — | — | -50.2%#7 | — |
| QNCX | $30M#6 | 0.2x#2 | — | — | — | -47.8%#12 | — | — | — | — | -90.7%#15 | — |
| CVM | $27M#8 | — | 2.5x#6 | 103.9x#4 | 65.5%#1 | 5.6%#6 | -9396.5%#5 | -231.9%#8 | — | — | -82.6%#14 | — |
| GRMLW | $28M#7 | — | 0.5x#3 | — | — | -71.6%#13 | — | -18.2%#2 | -14.6%#1 | — | -33.1%#3 | — |
| JSPR | $21M#10 | — | 14.6x#10 | — | — | 100.0%#1 | — | -0.0%#1 | — | — | -76.1%#13 | — |
| PHGE | $49M#1 | 0.1x#1 | 4.5x#8 | — | — | -104.2%#14 | — | -333.2%#10 | -377.8%#3 | — | -97.9%#16 | — |
| BCDA | $17M#11 | — | 6.3x#9 | — | -100.0%#7 | -3.5%#8 | — | -304.7%#9 | — | — | -27.0%#2 | — |
| DYAI | $16M#12 | — | — | 5.0x#3 | -11.6%#2 | -26.8%#11 | -232.8%#1 | — | — | — | -56.9%#9 | — |
| PASG | $15M#13 | — | 3.4x#7 | — | — | 29.7%#3 | — | -1021.6%#11 | — | — | -34.8%#4 | — |
| BCLI | $13M#14 | — | — | — | — | 11.3%#5 | — | — | — | — | -1.7%#1 | — |
| INTS | $13M#15 | — | 1.4x#5 | — | — | 28.7%#4 | — | -126.0%#6 | — | — | -36.6%#5 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice